A Screening Test for Cognitive Therapy?
Predicting which patients may benefit from treatment for depression
Philadelphia, PA – 18 April 2011 - The scientific foundation of psychiatry is growing rapidly, yet it is a branch of medicine distinctive for the relative absence of biological tests in routine clinical practice.
The most effective treatments for depression, including cognitive therapy, are successful for only about half the patients to whom they are given. The ability to predict those individuals who would be most likely to benefit from such treatment would reduce individuals’ recovery times, eliminate the delivery of ineffective treatments, and reduce the high costs of care.
Recent work suggests that reasonable predictions can be made about which patients will respond to cognitive therapy if they are given a brain scan. Unfortunately, brain scans are too expensive, time-intensive, and fraught with technical challenges to use on a routine basis.
Now, researchers at the University of Pittsburgh and the University of Pennsylvania are reporting a potential alternative. Their findings are published in the current issue of Biological Psychiatry.
“We have shown that a quick, inexpensive, and easy to administer physiological measure, pupil dilation in response to emotional words, not only reflects activity in brain regions involved in depression and treatment response but can predict which patients are likely to respond to cognitive therapy,” explained Dr. Greg Siegle, corresponding author on the study.
“According to proverb, the eye is the mirror of the soul or, in this case, the brain. The essential finding of this study is that that activity in the brain's cortical emotion regulatory systems is strongly related to pupil size when people are viewing emotion-laden words,” commented Dr. John Krystal, Editor of Biological Psychiatry. “It is because of this relationship between eye and brain that pupil measurements predict the response to cognitive therapy.
Cognitive therapy is a type of psychotherapy designed to help individuals overcome difficulties by modifying negative or irrational thoughts and behavior, which, in turn, can improve mood and reduce stress. It is usually completed in weekly sessions, with 10-20 sessions being effective for most individuals who benefit.
This was a relatively small study, so the work still requires replication. But, the authors have high hopes that this technology could eventually be used regularly to improve treatment response rates in mental health clinics.
# # #
Notes to Editors:
The article is “Remission Prognosis for Cognitive Therapy for Recurrent Depression Using the Pupil: Utility and Neural Correlates” by Greg J. Siegle, Stuart R. Steinhauer, Edward S. Friedman, Wesley S. Thompson, and Michael E. Thase. Siegle, Steinhauer, Friedman, and Thase are affiliated with the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Steinhauer is also with the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. Thase is also affiliated with the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania. Thompson is affiliated with the University of California, San Diego, San Diego, California. The article appears in Biological Psychiatry, Volume 69, Number 8 (April 15, 2011), published by Elsevier.
The authors’ disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological-Psychiatry-Editorial-Disclosures-7-22-10.pdf.
Full text of the article mentioned above is available upon request. Contact Chris J. Pfister at firstname.lastname@example.org to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length reports of novel results, commentaries, case studies of unusual significance, and correspondence judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise reviews and editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry ( www.sobp.org/journal) is ranked 4th out of 117 Psychiatry titles and 13th out of 230 Neurosciences titles in the 2009 ISI Journal Citations Reports® published by Thomson Reuters. The 2009 Impact Factor score for Biological Psychiatry has increased to 8.926.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Chris J. Pfister
Strategic Marketing Manager - Elsevier